NCT06200584

Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics

Synergistic Effect of Vitamin E & D in Reducing the Risk of Effects Associated With Atypical Antipsychotics

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: Dr Rabia Arshad · Academic / Other
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Atypical antipsychotic drugs are commonly used to treat psychiatric illnesses but they are significantly associated with side effects including acute dystonia, akathisia, parkinsonism (rigidity and tremor), tardive dyskinesia, bradycardia, hypotension, impotence, sleepiness, seizures, severe dreams or nightmares, and hyperprolactinaemia. Vitamin D and E, have been the focus of much research in the past fifteen years, which has revealed multiple roles in the development and function of the body. According to mounting data from the domains of epidemiology and neuroscience, vitamin D and E deficiency have been related to a number of neuropsychiatric issues as well as neurodegenerative diseases. Additionally, antioxidants like vitamin E help to prevent inflammation and highly reactive oxygen molecules from damaging normal cells. The use of vitamin E and D supplements has been suggested to improve the overall outcomes of psychiatric illnesses and neurological diseases. However, the synergistic effect of vitamins E and D in reducing the risk of the adverse effects associated with atypical antipsychotics and improvement in psychiatric illness is not well understood. Therefore, this study was designed to investigate the potential synergistic effect of vitamin E and D supplements for reducing the adverse effects associated with atypical antipsychotics.

Detailed description

Inclusion Criteria: 1\. Patients using antipsychotic medications such as quetiapine, olanzapine, or risperidone 3. Participants who are between the ages of 20 - 70 years 3. Both gender patients male and female 4. Patients with no other chronic morbidity

Conditions

• Antipsychotics and Neuroleptics Toxicity

Interventions

Type	Name	Description
DRUG	Risperidone	Antipsychotic Agent
DRUG	Olanzapine	Antipsychotic Agent
DRUG	Quetiapine	Antipsychotic Agent
DRUG	Risperidone and Vitamin D and Vitamin E	vitamin
DRUG	Olanzapine and Vitamin D and Vitamin E	vitamin and Antipsychotic agent
DRUG	Quetiapine and Vitamin D and Vitamin E	Vitamin and Antipsychotic agents

Timeline

• Start date: 2021-01-01
• Primary completion: 2021-06-01
• Completion: 2021-06-10
• First posted: 2024-01-11
• Last updated: 2024-01-11

Locations

1 site across 1 country: Pakistan